Companies: 10,795·Total market cap: $144.5T
Landos Biopharma, Inc.

Landos Biopharma, Inc.

LABPNASDAQHealthcare
$22.93
+$0.13(+0.57%)
Market Cap$71675511
P/E Ratio
52W High$22.94
52W Low$3.145
SEC Filings

Landos Biopharma, Inc. (LABP) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001785345 · LABP · NASDAQ · as of Jun 9, 2026

Filing snapshot

211
Total Filings
15-12G
Latest Form
2024-06-03
Most Recent
2021
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001785345 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2024-04-16
Fiscal Year End
Apr 16, 2024
Accession No.
0001193125-24-097023
Primary Document
d816715d10ka.htm
Source: data.sec.gov · CIK 0001785345 · Accession 0001193125-24-097023

Latest Key Filings

10-QQuarterly Report
10-Q
2024-05-09
8-KCurrent Report
8-K
2024-05-23Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
15-12G15-12G
15-12G
2024-06-03
View
RWRW
RW
2024-05-23
View
S-8 POSS-8 POS
S-8 POS
2024-05-23
View
S-8 POSS-8 POS
S-8 POS
2024-05-23
View
S-8 POSS-8 POS
S-8 POS
2024-05-23
View
S-8 POSS-8 POS
S-8 POS
2024-05-23
View
8-KCurrent Report
8-K
2024-05-23
View
25-NSE25-NSE
25-NSE
2024-05-23
View
8-KCurrent Report
8-K
2024-05-23
View
10-QQuarterly Report
10-Q
2024-05-09
View
DEFM14ADEFM14A
DEFM14A
2024-04-25
View
10-K/AAnnual Report (Amended)
10-K/A
2024-04-16
View
PREM14APREM14A
PREM14A
2024-04-15
View
SC 13D/ASC 13D/A
SC 13D/A
2024-04-10
View
SC 13D/ASC 13D/A
SC 13D/A
2024-04-10
View
Showing 1–15 of 156 filingsForm 4 / 144 hidden· 211 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001785345  |  Exchange: NASDAQ · Healthcare

Landos Biopharma, Inc. (NASDAQ: LABP) has submitted 211 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001785345, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Landos Biopharma, Inc.'s most comprehensive regulatory disclosure. The most recent Landos Biopharma, Inc. 10-K was filed on 2024-04-16 for fiscal year ending 2024. Historical LABP 10-K annual reports are available from 2019 through 2024.

Investors researching Landos Biopharma, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09

Frequently Asked Questions

LABP SEC Filings · 8 questions

Landos Biopharma, Inc. (LABP) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 211 filings and access original documents at no cost. Landos Biopharma, Inc.'s CIK is 0001785345.

LABP SEC filingsLandos Biopharma, Inc. SEC documentsfind LABP 10-K